Cambridge Epigenetix Stock
Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Sign up today and learn more about Cambridge Epigenetix Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Cambridge Epigenetix Stock
Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine and important diagnostic screening and detection tests for colorectal cancer and other common tumours to a simple blood draw. CEGX is pioneering the field of clinical epigenetics, and the company’s technology has proven the link between the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) and disease. Research has revealed a wide range of diagnostic and prognostic applications for 5hmC, now one of the most important biomarkers in the quest to improve human health. Spun-out of the University of Cambridge in 2012, CEGX was founded to develop and commercialise the science of world leading researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who identified the essential role of the TET enzymes and 5hmC in development and disease. A privately held company headquartered in Cambridge, UK, Cambridge Epigenetix is supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital, DNA Capital and the University of Cambridge.
Funding History
October 2014 | $5.5M |
---|---|
March 2016 | $21.0M |
September 2018 | $30.0M |
November 2020 | $8.0M |
November 2021 | $88.0M |
Management
Co-Founder and Director
Shankar Balasubramian
Co-Founder and Director
Bobby Yerramilli-Rao
Senior Vice President of Research
Joanna Holbrook
Board Observer
Roelof Botha
Member of the Board of Directors
Bobby Yerramilli-Rao
Chief Financial Officer
Fiona Stewart
Senior Vice President of Operations & Site Head
Gareth Ridge
Facilities & IT Manager
Nathan Williams
Associate Director
Martin Murphy
Consultant Advisor
Nick McCooke
Scientific Advisor
Wolf Reik
Press
patents - Apr, 14 2024
Methods for analyzing nucleic acidsgenomeweb - Jun, 18 2022
People in the News at Quantum-Si, Cambridge Epigenetix, Sema4, Moreglobenewswire - Jun, 14 2022
Cambridge Epigenetix Names Peter Fromen as Chief Executive Officernews - Jan, 7 2022
Last Year Was A Blockbuster For VC-Backed Startups. Here Are Our Top 9 Predictions For What 2022 Has In Storenews - Jan, 5 2022
For 2022, Here’s What Startups Are Doing To Extend Our Lifespans